The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Open accessAbstract
Tumours respond differently to immunotherapies compared with chemotherapeutic drugs, raising questions about the assessment of changes in tumour burden-a mainstay of evaluation of cancer therapeutics that provides key information about objective response and disease progression. A consensus guideline-iRECIST-was developed by the RECIST working group for the use of modified Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) in cancer immunotherapy trials, to ensure consistent design and data collection, facilitate the ongoing collection of trial data, and ultimate validation of the guideline. This guideline describes a standard approach to solid tumour measurements and definitions for objective change in tumour size for use in trials in which an immunotherapy is used. Additionally, it defines the minimum datapoints required from future trials and those currently in development to facilitate the compilation of a data warehouse to use to later validate iRECIST. An unprecedented number of trials have been done, initiated, or are planned to test new immune modulators for cancer therapy using a variety of modified response criteria. This guideline will allow consistent conduct, interpretation, and analysis of trials of immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other studies using TβRI small molecule inhibitors confirmed attenuation of metastasis in various carcinoma types325.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [325]
In the citing paper
“TGF-β inhibition as monotherapy, using neutralizing antibodies, ligand traps or receptor kinase inhibitors, has seen some success in mouse models of carcinomas, primarily in reducing metastatic spread rather than reducing growth of the primary tumor325 (Table 1).”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [325]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Self-citationNew Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Self-citationAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Cited by
Sorted by citations
Items 501–600 of 1,001
Rogado, J., Romero-Laorden, N., Sánchez-Torres, J. M., Ramos-Levi, A. M., Pacheco-Barcía, V., Ballesteros, A. I., Arranz, R., Lorenzo, A., Gullón, P., Garrido, A., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1751548 · Cited by 37
Cantini, L., Belderbos, R. A., de Gooijer, C. J., Dumoulin, D. W., Cornelissen, R., Baart, S. J., Burgers, J. A., Baas, P., & Aerts, J. G. J. V. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-19-686 · Cited by 34
Immunotherapy as sensitizer for local radiotherapy
Vanneste, B. G. L., Limbergen, E. J. V., Dubois, L. J., Samarska, I. V., Wieten, L., Aarts, M. J. B., Marcelissen, T. A. T., & Ruysscher, D. D. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1832760 · Cited by 38
Danylesko, I., Shouval, R., Shem‐Tov, N., Yerushalmi, R., Jacoby, E., Besser, M. J., Shimoni, A., Davidson, T., Beider, K., Mevorach, D., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01156-y · Cited by 37
Cabibbo, G., Celsa, C., Enea, M., Battaglia, S. L., Rizzo, G. E. M., Busacca, A., Matranga, D., Attanasio, M., Reig, M., Craxı̀, A., et al. (2020) · Cancers · doi:10.3390/cancers13010090 · Cited by 37
Kok, P., Yoon, W.-H., Lord, S. J., Marschner, I. C., Friedlander, M. L., & Lee, C. K. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00108 · Cited by 37
Lopci, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215160 · Cited by 37
Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives
Luo, W., Wang, Z., Zhang, T., Yang, L., Xian, J., Li, Y., & Li, W. (2021) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbab027 · Cited by 40
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications
Cabo, M., Offringa, R., Zitvogel, L., Kroemer, G., Muntasell, A., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1371896 · Cited by 37
Govindan, R., Aggarwal, C., Antonia, S. J., Davies, M. J., Dubinett, S. M., Ferris, A. A., Forde, P. M., Garon, E. B., Goldberg, S. B., Hassan, R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003956 · Cited by 46
Self-citationFDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients
Leger, M. C., Routy, B., & Juneau, D. (2022) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.04.010 · Cited by 37
Castello, A., Rossi, S., Toschi, L., & Lopci, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061251 · Cited by 36
Smussi, D., Mattavelli, D., Paderno, A., Gurizzan, C., Lorini, L., Romani, C., Bignotti, E., Grammatica, A., Ravanelli, M., & Bossi, P. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102644 · Cited by 38
Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients
Al-Danakh, A., Safi, M., Jian, Y., Yang, L., Zhu, X., Chen, Q., Yang, K., Wang, S., Zhang, J., & Yang, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1348189 · Cited by 37
Knowledge mapping of immunotherapy for breast cancer: A bibliometric analysis from 2013 to 2022
Qu, F., Wang, G., Wen, P., Liu, X., & Zeng, X. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2335728 · Cited by 38
“51 Pathological complete response (pCR) after neoadjuvant chemotherapy is considered an alternative endpoint for long-term clinical outcomes, which might be less appropriate to evaluate long-term immune memory responses that could sustain therapeutic effects and prevent relapses.”
Ellingson, B. M., Sanvito, F., Cloughesy, T. F., Huang, R. Y., Villanueva-Meyer, J. E., Pope, W. B., Barboriak, D. P., Shankar, L. K., Smits, M., Kaufmann, T. J., et al. (2024) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8396 · Cited by 36
Self-citationCao, L., Zhong, N., Chen, Y., Li, Z., Wang, G.-R., Xiao, Y., Liu, X.-H., Jia, J., Liu, B., & Bu, L. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217095 · Cited by 38
Novel Combination Immunotherapy and Clinical Activity in Patients With HPV-Associated Cancers
Floudas, C. S., Goswami, M., Donahue, R. N., Pastor, D. M., Redman, J. M., Brownell, I., Turkbey, E. B., Cordes, L. M., Steinberg, S. M., Manu, M., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2024.6998 · Cited by 38
Wong, D. J., Lee, J. J. X., Choo, S. P., Thng, C. H., & Hennedige, T. P. (2019) · Immunotherapy · doi:10.2217/imt-2018-0126 · Cited by 36
Principles of Immunotherapy in Melanoma
Onitilo, A. A., & Wittig, J. A. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.09.009 · Cited by 38
Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
Refae, S., Gal, J., Brest, P., Giacchero, D., Borchiellini, D., Ebran, N., Peyrade, F., Guigay, J., Milano, G. A., & Saâda-Bouzid, E. (2020) · Scientific Reports · doi:10.1038/s41598-020-60437-0 · Cited by 37
Seban, R., Assié, J., Leprieur, E. G., Massiani, M.-A., Soussan, M., Bonardel, G., CHOUAID, C., Playe, M., Goldfarb, L., Duchemann, B., et al. (2020) · Cancers · doi:10.3390/cancers12082234 · Cited by 37
Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
Shen, P., Han, L., Ba, X., Qin, K., & Tu, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.678409 · Cited by 36
Radiomics in the Setting of Neoadjuvant Radiotherapy: A New Approach for Tailored Treatment
Nardone, V., Boldrini, L., Grassi, R., Franceschini, D., Morelli, I., Becherini, C., Loi, M., Greto, D., & Desideri, I. (2021) · Cancers · doi:10.3390/cancers13143590 · Cited by 37
18 F‐FDG PET / CT features of immune‐related adverse events and pitfalls following immunotherapy
Cherk, M. H., Nadebaum, D. P., Barber, T. W., Beech, P., Haydon, A. M., & Yap, K. S. K. (2022) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13390 · Cited by 36
MSI colorectal cancer, all you need to know
Flecchia, C., Zaanan, A., Lahlou, W., Basile, D., Broudin, C., Gallois, C., Pilla, L., Karoui, M., Manceau, G., & Taı̈eb, J. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.101983 · Cited by 40
Feola, T., Carbonara, F., Verrico, M., Crescenzo, R. M. D., Gianno, F., Colonnese, C., Arcella, A., Alcubierre, D. D., Tomao, F., Esposito, V., et al. (2022) · Cancers · doi:10.3390/cancers14174093 · Cited by 36
“For such reasons, modified radiological RECIST criteria, such as the immune-related RECIST (irRECIST) or immune-modified (imRECIST), have been proposed [29–31] and early evaluation and follow-up (6–12 weeks or even 4–8 weeks) may allow recognizing such eventuality [28,29,31].”
MethodPET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
Gao, Y., Wu, C., Chen, X., Ma, L., Zhang, X., Chen, J., Liao, X., & Liu, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1049043 · Cited by 36
“iRECIST, classify the initial discovery of the suspected progression as initially unconfirmed progressive disease (iUPD) (60).”
Cheng, Y., Chen, Z., Huang, J.-J., & Shao, D. (2023) · European Radiology · doi:10.1007/s00330-023-09922-4 · Cited by 38
Li, X., Chen, J., Liu, C., Song, X., Zhang, Y., Zhao, H., Yan, S., Jia, W., Wu, Z., Guo, Y., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03356-5 · Cited by 36
“This approach allows for the identification of atypical responses, such as delayed responses that may occur after pseudoprogression, thereby potentially preventing early treatment discontinuation due to pseudo-progression [20].”
BackgroundA review of immune therapy in cancer and a question: can thermal therapy increase tumor response?
Bull, J. M. (2017) · International Journal of Hyperthermia · doi:10.1080/02656736.2017.1387938 · Cited by 37
Castello, A., Rossi, S., Toschi, L., Mansi, L., & Lopci, E. (2020) · Cancers · doi:10.3390/cancers12061373 · Cited by 37
Feinberg, B. A., Zettler, M. E., Klink, A. J., Lee, C. H., Gajra, A., & Kish, J. K. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.36741 · Cited by 35
CT based radiomic approach on first line pembrolizumab in lung cancer
Zerunian, M., Caruso, D., Zucchelli, A., Polici, M., Capalbo, C., Filetti, M., Mazzuca, F., Marchetti, P., & Laghi, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-86113-5 · Cited by 35
Amin, N., Maroun, C. A., Asmar, M. E., Alkhatib, H. H., Guller, M., Herberg, M. E., Zhu, G., Seiwert, T. Y., Pardoll, D. M., Eisele, D. W., et al. (2021) · Head & Neck · doi:10.1002/hed.26935 · Cited by 35
Crombé, A., Dugage, M. R., & Italiano, A. (2022) · 癌症：英文版 · doi:10.1002/cac2.12373 · Cited by 38
“Likewise, the PET response criteria for solid tumors (PERCIST) have been replaced by immune-PERCIST and PET response evaluation criteria for immunotherapy [108–110].”
MethodBozorgmehr, N., Okoye, I., Mashhouri, S., Lu, J., Koleva, P. T., Walker, J. W. T., & Elahi, S. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006595 · Cited by 34
Wyatt, A. W., Litière, S., Bidard, F., Cabel, L., Dyrskjøt, L., Karlovich, C., Pantel, K., Petrie, J., Philip, R., Andrews, H. S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1883 · Cited by 34
“Immunotherapy response assessment poses particularly unique challenges and although modified RECIST 1.1 guidelines for immune-based therapeutics (iRECIST) were developed, they still require validation (7,8).”
InfluentialSelf-citationTreatment Beyond Progression With Immune Checkpoint Inhibitors—Known Unknowns
Blumenthal, G. M., Theoret, M. R., & Pazdur, R. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1819 · Cited by 34
Rafei-Shamsabadi, D. A., Lehr, S., von Bubnoff, D., & Meiß, F. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02377-x · Cited by 35
Kijima, T., Yamamoto, H., Saito, K., Kusuhara, S., Yoshida, S., Yokoyama, M., Matsuoka, Y., Numao, N., Sakai, Y., Matsubara, N., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02709-2 · Cited by 34
Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice
Roberto, M., Botticelli, A., Panebianco, M., Aschelter, A. M., Gelibter, A. J., Ciccarese, C., Minelli, M., Nuti, M., Santini, D., Laghi, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.657639 · Cited by 36
Guidelines for clinical evaluation of anti‐cancer drugs
Minami, H., Kiyota, N., Kimbara, S., Ando, Y., Shimokata, T., Ohtsu, A., Fuse, N., Kuboki, Y., Shimizu, T., Yamamoto, N., et al. (2021) · Cancer Science · doi:10.1111/cas.14967 · Cited by 36
Paderi, A., Gambale, E., Botteri, C., Giorgione, R., Lavacchi, D., Brugia, M., Mazzoni, F., Giommoni, E., Bormioli, S., Amedei, A., et al. (2021) · Molecules · doi:10.3390/molecules26195789 · Cited by 35
Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma
McLean, L. S., Lim, A. M. L., Webb, A., Cavanagh, K., Thai, A. A., Magarey, M. J. R., Fox, C., Kleid, S. M., & Rischin, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.796197 · Cited by 35
Wermke, M., Holderried, T. A. W., Luke, J. J., Morris, V. K., Alsdorf, W. H., Wetzko, K., Andersson, B. S., Wistuba, I. I., Parra, E. R., Hossain, M. B., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008668 · Cited by 33
“21”
Smoragiewicz, M., Bogaerts, J., Calvo, E., Marabelle, A., Perrone, A., Seymour, L., Shalabi, A., Siu, L. L., Tabernero, J. M., Giaccone, G., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy398 · Cited by 32
Self-citationAyati, N., Lee, S. T., Zakavi, S. R., Cheng, M., Lau, E. W. F., Parakh, S., Pathmaraj, K., & Scott, A. M. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.254508 · Cited by 33
Zhou, C., Wang, J., Wang, B., Cheng, Y., Wang, Z., Han, B., Lü, Y., Wu, G., Zhang, L., Song, Y., et al. (2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2021.101.13 · Cited by 32
Bauckneht, M., Genova, C., Rossi, G., Rijavec, E., Bello, M. G. D., Ferrarazzo, G., Tagliamento, M., Donegani, M., Biello, F., Chiola, S., et al. (2021) · Cancers · doi:10.3390/cancers13133117 · Cited by 30
Cabezas-Camarero, S., & Pérez‐Segura, P. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103569 · Cited by 33
de Leon, A. D., Pirasteh, A., da Costa, D. N., Kapur, P., Hammers, H. J., Brugarolas, J., & Pedrosa, I. (2019) · Radiographics · doi:10.1148/rg.2019180178 · Cited by 34
Clinical Perineural Invasion and Immunotherapy for Head and Neck Cutaneous Squamous Cell Carcinoma
Wu, M. P., Reinshagen, K. L., Cunnane, M. B., Shalhout, S. Z., Kaufman, H. L., Miller, D. M., & Emerick, K. S. (2021) · The Laryngoscope · doi:10.1002/lary.29953 · Cited by 32
Nakamoto, R., Zaba, L. C., Rosenberg, J., Reddy, S. A., Nobashi, T. W., Davidzon, G., Aparici, C. M., Nguyen, J., Moradi, F., Iagaru, A. H., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04792-0 · Cited by 32
Middleton, M. R., Höeller, C., Michielin, O. A., Robert, C., Caramella, C., Öhrling, K., & Hauschild, A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0994-4 · Cited by 31
Self-citationImpact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer
Chambers, L., Michener, C. M., Rose, P. G., Reizes, O., Yao, M., & Vargas, R. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.01.015 · Cited by 35
Cabanié, C., Ammari, S., Hans, S., Pobel, C., Laparra, A., Danlos, F., Chanson, N., Dolidon, S., Seban, R., Voisin, A.-L., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.07.015 · Cited by 32
Kim, H. I., Lim, J., & Shim, J. H. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03727-y · Cited by 32
Zhou, M., Zhang, C., Nie, J., Sun, Y., Xu, Y., Wu, F., Huang, Y., Li, S., Wang, Y., Zhou, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.764189 · Cited by 32
Qin, S., Li, J., Zhong, H., Jin, C., Chen, L., Yuan, X., Fan, Q., Chen, K., Cao, P., Xiao, J., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02001-3 · Cited by 33
“Subsequent treatment for patients with confirmed PD at the next assessment (≥4 weeks from the first documented PD) by response criteria for cancer immunotherapy trials (iRECIST) [20] was at the discretion of the investigator.”
BackgroundTong, T. M. L., Burgmans, M. C., Speetjens, F. M., van Erkel, A. R., van der Meer, R. W., van Rijswijk, C. S. P., Jonker-Bos, M. A., Roozen, C. F. M., Sporrel-Blokland, M., Lutjeboer, J., et al. (2023) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-022-03338-1 · Cited by 34
“Response was also evaluated according to immune-related RECIST (irRECIST) and modified RECIST (mRECIST) criteria [27, 28].”
MethodImmunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
Russano, M., Cava, G. L., Cortellini, A., Citarella, F., Galletti, A., Fazio, G. R. D., Santo, V., Brunetti, L., Vendittelli, A., Fioroni, I., et al. (2023) · Current Oncology · doi:10.3390/curroncol30020181 · Cited by 34
Carbone, M. L., Capone, A., Guercio, M., Reddel, S., Silvestris, D. A., Lulli, D., Ramondino, C., Peluso, D., Quintarelli, C., Volpe, E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1197630 · Cited by 31
Bergman, P. J. (2023) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2023.12.002 · Cited by 37
O’Hare, P., Cooney, T. M., de Blank, P. M. K., Gutmann, D. H., Kieran, M. W., Milde, T., Fangusaro, J., Fisher, M. J., Avula, S., Packer, R. J., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae074 · Cited by 31
“43 47 Possible “pseudoprogression (PsP)” is now recognized in both adult and pediatric low-grade glioma post-radiation therapy for both photon-based and proton beam therapy.”
BackgroundXiang, X., Wang, K., Zhang, H., Mou, H., Shi, Z., Tao, Y., Song, H., Lian, Z., Wang, S., Lu, D., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0627 · Cited by 36
Rebuzzi, S. E., Perrone, F., Bersanelli, M., Bregni, G., Milella, M., & Buti, S. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1680286 · Cited by 31
Davis, A. A., Iams, W. T., Chan, D., Oh, M. S., Lentz, R. W., Peterman, N., Robertson, A., Shah, A., Srivas, R., Wilson, T., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1060 · Cited by 33
Robinson, C., Xu, M. M., Nair, S. K., Beasley, G. M., & Rhodin, K. E. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2702063 · Cited by 31
Imaging immunity in patients with cancer using positron emission tomography
Hegi‐Johnson, F., Rudd, S. E., Hicks, R. J., Ruysscher, D. D., Trapani, J. A., John, T., Donnelly, P. S., Blyth, B. J., Hanna, G. G., Everitt, S., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00263-x · Cited by 33
Role of radiomics in predicting immunotherapy response
Kothari, G. (2022) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13426 · Cited by 33
Reviewing RECIST in the Era of Prolonged and Targeted Therapy
Morgan, R. L., & Camidge, D. R. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.015 · Cited by 35
Santiago-Sánchez, G. S., Fabian, K. P., & Hodge, J. W. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2308097 · Cited by 31
“23,67 To determine whether a treated patient is showing immune checkpoint primary resistance, a confirmatory scan needs to be performed to validate PD. 23 On the other hand, the taskforce disagreed on which response evaluation criteria – Response Evaluation Criteria in Solid Tumors 68 or RECIST 1.1—was to be employed…”
BackgroundMethodInfluentialHuang, Z., Zeng, L., Ruan, Z., Zeng, Q., Yan, H., Jiang, W., Yi, X., Zhou, C., Yang, H., Liu, L. K., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04181-w · Cited by 30
“A Tumor responses were classified and confirmed according to RECIST criteria (version 1.1) 38 .”
InfluentialRetractedTsimberidou, A. M., Levit, L. A., Schilsky, R. L., Averbuch, S. D., Chen, D. S., Kirkwood, J. M., McShane, L. M., Sharon, E., Mileham, K. F., & Postow, M. A. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00145 · Cited by 30
Role of noninvasive molecular imaging in determining response
Marciscano, A. E. E., & Thorek, D. L. J. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.07.006 · Cited by 31
Atypical Response Patterns in Patients Treated With Nivolumab
Thomas, R., Somarouthu, B., Alessandrino, F., Kurra, V., & Shinagare, A. B. (2019) · American Journal of Roentgenology · doi:10.2214/ajr.18.20938 · Cited by 30
Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology
Signore, A., Lauri, C., Auletta, S., Anzola, L. K., Galli, F., Casali, M., Versari, A., & Glaudemans, A. W. J. M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050681 · Cited by 30
Saxena, P., Singh, P. K., Malik, P. S., & Singh, N. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00768-2 · Cited by 30
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
Helland, Å., Russnes, H. G., Fagereng, G. L., Al-Shibli, K. I., Andersson, Y., Berg, T., Bjørge, L., Blix, E. S., Bjerkehagen, B., Brabrand, S., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03432-5 · Cited by 30
iRECIST: A clarification of tumour response assessment in the immunotherapy era
Ferté, C., & Marabelle, A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.015 · Cited by 30
Hu, Y., Cai, Z., Huang, R., Wang, D., Ju, H., & Chen, D. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02192-8 · Cited by 29
“Among these patients, 10 participants exhibited PD by RECIST 1.1 [24] and were defined as patients resistant to anti-PD-1 therapy, while 8 participants showed PR and were defined as patients responsive to anti-PD-1 therapy.”
InfluentialMorris, V. K., Parseghian, C. M., Bahrambeigi, V., Abdelfattah, N., Xiao, L., Agrawal, A., Lin, K., Raghav, K. P. S., Wolff, R. A., Dasari, A. N., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.08.002 · Cited by 32
Flynn, M. J., & Larkin, J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1369956 · Cited by 30
Dercle, L., Lü, L., Lichtenstein, P., Yang, H., Wang, D., Zhu, J., Wu, F., Piessevaux, H. H., Schwartz, L. H., & Zhao, B. (2017) · JCO Clinical Cancer Informatics · doi:10.1200/cci.17.00108 · Cited by 29
Self-citationCastello, A., Grizzi, F., Qehajaj, D., Rahal, D., Lutman, R. F., & Lopci, E. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1488254 · Cited by 29
TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy
Lin, R., Coleman, R. L., & Yuan, Y. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz049 · Cited by 29
Rimola, J., da Fonseca, L. G., Sapena, V., Perelló, C., Guerrero, A. F., Torner, M., Pons, M., de la Torre‐Aláez, M., Márquez, L., Calleja, J. L., et al. (2020) · European Journal of Radiology · doi:10.1016/j.ejrad.2020.109484 · Cited by 27
CLEVERS, M. R., Kastelijn, E. A., Peters, B. J. M., Kelder, H. C., & Schramel, F. M. N. H. (2021) · Anticancer Research · doi:10.21873/anticanres.14839 · Cited by 29
Park, C., Jeong, D. Y., Choi, Y., Oh, Y. J., Kim, J., Ryu, J., Paeng, K., Lee, S., Ock, C., & Lee, H. Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1038089 · Cited by 30
Mesti, T., Kuhar, C. G., & Ocvirk, J. (2023) · Biomedicines · doi:10.3390/biomedicines11030749 · Cited by 29
“Patients that developed irAEs also had significantly better progression-free survival (PFS) [14].”
BackgroundTowards evidence-based response criteria for cancer immunotherapy
Garralda, E., Laurie, S. A., Seymour, L., & de Vries, E. G. E. (2023) · Nature Communications · doi:10.1038/s41467-023-38837-3 · Cited by 29
Self-citationA call to action to advance patient‐focused and decentralized clinical trials
Harvey, R. D., Miller, T. M., Hurley, P. A., Thota, R., Black, L. J., Bruinooge, S. S., Boehmer, L., Fleury, M. E., Kamboj, J., Rizvi, M. A., et al. (2024) · Cancer · doi:10.1002/cncr.35145 · Cited by 31
Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons
Aquilanti, E., & Brastianos, P. K. (2020) · Neurosurgery · doi:10.1093/neuros/nyaa095 · Cited by 30
Liu, Y., Chen, W., Ruan, R., Zhang, Z., Wang, Z., Guan, T., Lin, Q., Tang, W., Deng, J., Wang, Z., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05262-z · Cited by 33
“The evaluation of the efficacy of PD-inhibitors combined chemotherapy was performed according to iRE-CIST 1.1 criteria [29] using baseline-enhanced CT and follow-up CT scans.”
MethodInfluentialArita, Y., Kwee, T. C., Akın, O., Shigeta, K., Paudyal, R., Roest, C., Ueda, R., Lema-Dopico, A., Nalavenkata, S. B., Ruby, L. C., et al. (2025) · Insights into Imaging · doi:10.1186/s13244-024-01884-5 · Cited by 28
Self-citationGhita, M., Brown, K. H., Kelada, O. J., Graves, E. E., & Butterworth, K. T. (2019) · Cancers · doi:10.3390/cancers11020170 · Cited by 28
Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy
Coventry, B. J. (2019) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/2515135519862234 · Cited by 30
Himoto, Y., Veeraraghavan, H., Zheng, J.-T., Zamarin, D., Snyder, A., Capanu, M., Nougaret, S., Vargas, H., Shitano, F., Callahan, M., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00038 · Cited by 23
Economopoulou, P., Anastasiou, Μ., Papaxoinis, G., Spathas, N., Spathis, A., Oikonomopoulos, N., Kotsantis, I., Tsavaris, O., Gkotzamanidou, M. A., Gavrielatou, N., et al. (2021) · Cancers · doi:10.3390/cancers13020286 · Cited by 28
Metadata
- Authors
- Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., Hodi, F. S., Therasse, P., Hoekstra, O. S., Shankar, L. K., Wolchok, J. D., Ballinger, M., Caramella, C., & de Vries, E. G. E.
- Affiliations
- Queen's University (CA)
- European Organisation for Research and Treatment of Cancer (BE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- NewYork–Presbyterian Hospital (US)
- Mayo Clinic (US)
- National Institutes of Health (US)
- Harvard University (US)
- Institut de Recherches Internationales Servier (France) (FR)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Memorial Sloan Kettering Cancer Center (US)
- Genentech (US)
- Institut Gustave Roussy (FR)
- Corresponding author
- Seymour, Lesley
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 18
- Issue
- 3
- Pages
- e143-e152
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC5648544
- OpenAlex
- W2592144107
- Cited by
- 2,472
- References
- 37
- Citations by year
- 2026: 264 · 2025: 267 · 2024: 319 · 2023: 305 · 2022: 270 · 2021: 308 · 2020: 304 · 2019: 223 · 2018: 146 · 2017: 62
- FWCI
- 21.17
- Type
- journal article
- Language
- en
- Update notices
- erratum (2019-05-01)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Pure Amsterdam UMC (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Cancer Institute (U10CA011488, P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- iRECIST, cancer immunotherapy, response evaluation criteria, disease progression, immunomodulators, clinical trial data collection, data warehouse
- MeSH terms
- Humans, Immunotherapy, Neoplasms, Practice Guidelines as Topic, Disease Progression, Tumor Burden, Response Evaluation Criteria in Solid Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
